查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595128

非處方藥市場：按產品和分銷管道分類 - 2025-2030 年全球預測

Over The Counter Drugs Market by Product (Analgesics, Cough, Cold, & Flu Products, Dermatology Products), Distribution Channel (Hospital Pharmacies, Online Stores, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年非處方藥市值為4,641.4億美元，預計到2024年將達到5,048.6億美元，複合年成長率為8.86%，預計到2030年將達到8,412億美元。

非處方藥（OTC）市場是指無需處方箋即可購買的藥品，可以讓消費者獨立治療感冒、頭痛、過敏等小病。對成藥的需求是由自我治療需求不斷成長以及線上醫療保健資訊的不斷增加所推動的，這使得消費者能夠做出明智的健康決定。成藥的主要用途包括止痛藥、胃腸治療、皮膚科和營養食品。最終用途範圍主要包括透過藥局、超級市場和網路零售通路直接面對消費者的銷售。市場成長受到人口老化、零售藥局連鎖擴張以及監管轉向將處方藥重新分類為非處方藥以降低醫療保健成本等因素的顯著影響。數位健康平台將進一步改善消費者獲得成藥的機會，並為市場參與者提供肥沃的土壤。為了滿足永續性的永續發展需求，產品創新存在潛在機會，包括開發副作用較少的先進配方和環保包裝。儘管市場預計將穩定成長，但它面臨著重大挑戰，包括各個司法管轄區的嚴格監管以及誤用和過度使用非處方藥的風險。也存在一些限制，包括激烈的競爭和價格壓力，特別是來自學名藥的壓力。公司可以專注於創新領域，例如個人化 OTC 解決方案，利用人工智慧和機器學習來分析客戶資料並提供客製化產品。此外，整合遠端醫療服務可以提高消費者的信任和參與。該市場競爭激烈，但充滿活力，受到消費者對便利、安全和健康意識不斷變化的偏好的推動。強烈建議供應商所有者利用資料分析和策略夥伴關係關係來應對這些複雜性並確保主動遵守監管規範，同時利用新興趨勢來維持市場領先地位。

主要市場統計
基準年[2023] 4641.4億美元
預測年份 [2024] 5048.6億美元
預測年份 [2030] 8412億美元
複合年成長率（%） 8.86%

市場動態：揭示快速發展的非處方藥市場的關鍵市場洞察

非處方藥市場正在因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 治療輕微健康問題的經濟有效的方法
    • 減輕醫生負擔
    • 有利的法規結構
  • 市場限制因素
    • 由於市場飽和而存在替代藥物
  • 市場機會
    • 增加透過零售店和超級市場的管道
    • 技術進步與產品創新
  • 市場挑戰
    • 保持低價的壓力

波特五力：駕馭非處方藥市場的策略工具

波特五力是了解非處方藥市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對非處方藥市場的影響

外部宏觀環境因素對非處方藥市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解非處方藥市場的競爭狀況

對非處方藥市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣非處方藥市場供應商績效評估

FPNV定位矩陣是評估非處方藥市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 繪製非處方藥市場的成功之路

對於希望加強在全球市場的影響力的公司來說，非處方藥市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 治療輕微健康問題的經濟有效的方法
      • 減輕醫生負擔
      • 首選法規結構
    • 抑制因素
      • 由於市場飽和而存在替代藥物
    • 機會
      • 改善透過零售店和超級市場的訪問
      • 技術進步與產品創新
    • 任務
      • 保持低價的壓力
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 非處方藥市場：依產品

  • 止痛藥
  • 預防咳嗽、感冒和流感的產品
  • 皮膚科產品
  • 胃腸醫學
  • 眼科產品
  • 助眠劑
  • 維生素、礦物質和補充品
  • 減重/減肥產品

第7章 非處方藥市場：依分銷管道

  • 醫院藥房
  • 網路商店
  • 零售藥房

第8章：美洲非處方藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太非處方藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的非處方藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alembic Pharmaceuticals Ltd.
  • Alkem Laboratories Limited
  • Cipla, Inc.
  • Dr. Reddy's Laboratories
  • Glaxosmithkline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Ltd.
  • Johnson & Johnson Pvt. Ltd.
  • Lupin Limited
  • Mankind Pharma
  • Mylan Pharmaceuticals Pvt. Ltd. by Viatris
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-436297358D26

The Over The Counter Drugs Market was valued at USD 464.14 billion in 2023, expected to reach USD 504.86 billion in 2024, and is projected to grow at a CAGR of 8.86%, to USD 841.20 billion by 2030.

The Over-the-Counter (OTC) drugs market refers to pharmaceuticals that can be purchased without a prescription, allowing consumers to manage minor ailments such as colds, headaches, and allergies independently. The necessity of OTC drugs stems from the rising demand for self-medication and the increasing accessibility of healthcare information online, empowering consumers to make informed health decisions. Key applications of OTC drugs include pain relief, gastrointestinal treatments, dermatology, and dietary supplements. End-use scope primarily involves direct consumer sales through drugstores, supermarkets, and online retail channels. Market growth is significantly influenced by factors such as an aging population, the expansion of retail pharmacy chains, and regulatory shifts towards reclassifying prescription drugs as OTC to decrease healthcare costs. Digital health platforms further enhance consumer access to OTC medications, representing a fertile ground for market players. Potential opportunities lie in product innovation, such as developing advanced formulations with fewer side effects and eco-friendly packaging to meet the rising demand for sustainability. Despite robust growth prospects, the market faces significant challenges such as stringent regulations across varying jurisdictions and the risk of misuse or overuse of OTC products. Other limitations include intense competition and pricing pressures, especially from generic alternatives. Companies can focus on innovative areas such as personalized OTC solutions using AI and machine learning to analyze customer data for tailored product offerings. Additionally, integrating telehealth services can enrich consumer trust and engagement. The market's nature is highly competitive yet dynamic, driven by evolving consumer preferences towards convenience, safety, and health consciousness. Vendors are urged to leverage data analytics and strategic partnerships to navigate these complexities, ensuring proactive compliance with regulatory norms while capitalizing on emerging trends to sustain market leadership.

KEY MARKET STATISTICS
Base Year [2023] USD 464.14 billion
Estimated Year [2024] USD 504.86 billion
Forecast Year [2030] USD 841.20 billion
CAGR (%) 8.86%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Over The Counter Drugs Market

The Over The Counter Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Cost effective way to treat minor health issues
    • Reduced burden of the physician
    • Favorable regulatory framework
  • Market Restraints
    • Presence of substitute drug due to saturating market
  • Market Opportunities
    • Increased accessibility through retail outlets and supermarkets
    • Technological advancement and product innovation
  • Market Challenges
    • Pressure to keep the price low

Porter's Five Forces: A Strategic Tool for Navigating the Over The Counter Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Over The Counter Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Over The Counter Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Over The Counter Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Over The Counter Drugs Market

A detailed market share analysis in the Over The Counter Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Over The Counter Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Over The Counter Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Over The Counter Drugs Market

A strategic analysis of the Over The Counter Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Over The Counter Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Ltd., Alkem Laboratories Limited, Cipla, Inc., Dr. Reddy's Laboratories, Glaxosmithkline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Ltd., Johnson & Johnson Pvt. Ltd., Lupin Limited, Mankind Pharma, Mylan Pharmaceuticals Pvt. Ltd. by Viatris, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Over The Counter Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Analgesics, Cough, Cold, & Flu Products, Dermatology Products, Gastrointestinal Products, Ophthalmic Products, Sleeping Aids, Vitamins, Mineral, & Supplements, and Weight-Loss & Dietary Products.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Cost effective way to treat minor health issues
      • 5.1.1.2. Reduced burden of the physician
      • 5.1.1.3. Favorable regulatory framework
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of substitute drug due to saturating market
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased accessibility through retail outlets and supermarkets
      • 5.1.3.2. Technological advancement and product innovation
    • 5.1.4. Challenges
      • 5.1.4.1. Pressure to keep the price low
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Over The Counter Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Cough, Cold, & Flu Products
  • 6.4. Dermatology Products
  • 6.5. Gastrointestinal Products
  • 6.6. Ophthalmic Products
  • 6.7. Sleeping Aids
  • 6.8. Vitamins, Mineral, & Supplements
  • 6.9. Weight-Loss & Dietary Products

7. Over The Counter Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Stores
  • 7.4. Retail Pharmacies

8. Americas Over The Counter Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Over The Counter Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Over The Counter Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Ltd.
  • 2. Alkem Laboratories Limited
  • 3. Cipla, Inc.
  • 4. Dr. Reddy's Laboratories
  • 5. Glaxosmithkline PLC
  • 6. Glenmark Pharmaceuticals Limited
  • 7. Hetero Drugs Ltd.
  • 8. Johnson & Johnson Pvt. Ltd.
  • 9. Lupin Limited
  • 10. Mankind Pharma
  • 11. Mylan Pharmaceuticals Pvt. Ltd. by Viatris
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OVER THE COUNTER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OVER THE COUNTER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVER THE COUNTER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVER THE COUNTER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH, COLD, & FLU PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GASTROINTESTINAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OPHTHALMIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SLEEPING AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS, MINERAL, & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY WEIGHT-LOSS & DIETARY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 107. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023